Glioblastoma has been the subject of sustained clinical investigation across multiple research sites.

37 total trials for this combination

Showing top 10 of 37 trials

Trials

NCT ID	Title	Status	Phase
NCT02152982	Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	ACTIVE_NOT_RECRUITING	—
NCT01480479	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma	COMPLETED	PHASE3
NCT00884741	Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma	COMPLETED	PHASE3
NCT06556563	EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma	RECRUITING	—
NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	ACTIVE_NOT_RECRUITING	PHASE2
NCT02179086	Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	ACTIVE_NOT_RECRUITING	PHASE2
NCT02152982	Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	ACTIVE_NOT_RECRUITING	—
NCT03581292	Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations	ACTIVE_NOT_RECRUITING	PHASE2
NCT05095376	Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma	ACTIVE_NOT_RECRUITING	PHASE3
NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification	COMPLETED	PHASE3

Related Pages

All Glioblastoma trials All trials in Rochester, United States